Okwu mmalite nke Somaglutide
Somaglutide bụ ọgbọ ọhụrụ nke GLP-1 (glucagon dị ka peptide-1) analog nke Daminol na NovoNordisk mepụtara.Somaglutide bụ ụdị usoro onunu ogwu na-eme ogologo oge mepụtara dabere na ntọala nke Lilalutide, nke nwere mmetụta dị mma na ọgwụgwọ ụdị ọrịa shuga 2.Novo Nordisk emechaala 6 PChemicalbookbaseIIa ọmụmụ na Somaglutide injection, wee nyefee ngwa ndebanye aha ọgwụ ọhụrụ maka ọgwụ mgbochi kwa izu nke Somaglutide na US Food and Drug Administration (FDA) na Disemba 5, 2016 yana ngwa ikike ahịa (MAA) European Drug Anchịkwa (EMA).N'aka nke ọzọ, nkwadebe ọnụ otu ugboro kwa ụbọchị nke Somaglutide dị ugbu a na ngalaba ahụike III.
Ojiji
Somaglutide bụ usoro ọgwụgwọ na-eme ogologo oge nke emepụtara dabere na ntọala nke liraglutide, nke nwere mmetụta dị mma na ọgwụgwọ ụdị ọrịa shuga 2.
Nyocha
Semeglutide bụ analọg GLP-1 ọhụrụ a na-agba n'okpuru akpụkpọ ahụ otu ugboro n'izu.Somaglutide bụ analog GLP-1 na-arụ ọrụ ogologo oge nke Novo Nordisk mepụtara maka otu oge / w ntụtụ subcutaneous.E jiri ya tụnyere liraglutide, Somaglutide nwere eriri abụba ogologo yana ịba ụba hydrophobicity.Agbanyeghị, a na-eji obere yinye PEG gbanwee Somaglutide, yana hydrophilicity ya na-abawanye nke ukwuu.Mgbe mgbanwe PEG gasịrị, ọ bụghị naanị na ọ ga-ejikọta ya na albumin, na-ekpuchi ebe hydrolysis nke DPP-4 enzyme, kamakwa belata excretion nke akụrụ, gbasaa ọkara ndụ ndụ ma nweta mmetụta nke ogologo okirikiri.Novo Nordisk's Somaglutide kwụgburu DPP-4's Sigliptin, na GLP-1's malitere, ogologo-eme exenatide (ọ kwesịrị ka e mere ka mpi isi na isi na Lily si trucity. Iji ike emegbu kemgbe na ahịa ruo ogologo oge).N'ime nnwale ahụ, oke dose nke Somicalbook belatara A1C1.6%, na oke ibu dị arọ bụ kilogram 6.A na-eji Somaglutide nyochaa ịdị irè na nchekwa nke 1.0mg Somaglutide ma e jiri ya tụnyere 2.0mg Exenatide otu ugboro n'izu na ndị ọrịa 813 nwere ụdị ọrịa shuga 2.Oge nnwale ahụ bụ izu 56, ndị ọrịa were ọnụ 1-2 ọgwụ mgbochi ọrịa shuga n'otu oge.Na Disemba 2017, FDA kwadoro ọgwụ GLP-1 hypoglycemic kwa izu Somaglutide nke NovoNordisk mepụtara ka a na-ere ya n'okpuru aha ahia Ozempic.Dabere na data nnwale ụlọ ọgwụ, Ozempic nwere ike ibelata ọkwa HbA1c ma e jiri ya tụnyere placebo, Januvia nke Merck, Bydureon nke AstraZeneca na Lantus nke Sanofi.Ọgwụ ahụ gosikwara ike inyere ndị ọrịa aka ịkwụsị ibu arọ.
Oge nzipu: Dec-25-2022